StockData

Aurora Cannabis vs Cronos

ACB and CRON side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACB and CRON compare

Cronos grew revenue faster over the last twelve months (55.8% versus 11.0% for Aurora Cannabis).

Cronos scores higher on the StockData Score (15 against 6 for Aurora Cannabis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACBCRON
Size and price
Market cap–$1.3B
Share price$5.05$3.45
Change, 1 year8.1%34.8%
Change, 5 years−92.8%−30.0%
Beta (5Y)1.320.85
Employees–610
StockData Score
Total score615 (better)
Valuation score03 (better)
Growth score13 (better)
Performance score03 (better)
Health score56 (better)
Dividend score00
Valuation
P/E–20.3×
P/S–6.2×
P/B–1.2×
EV/EBITDA–38.3×
P/FCF–19.4×
FCF yield–5.1%
Fair value–$3.66
Margin of safety–5.7%
Growth
Revenue growth (TTM)11.0%55.8% (better)
Revenue growth, 5Y average5.5%25.7% (better)
Net income growth (TTM)–60.2%
EPS growth (TTM)−5450%70.0% (better)
Profitability
Gross margin42.6%46.6% (better)
Operating margin–3.4%
Net margin–28.0%
FCF margin–31.7%
Return on equity–5.4%
Return on invested capital–2.4%
Financial health
Debt / equity0.000.00
Current ratio5.9412.71 (better)
Altman Z-score–11.97
Piotroski F-score–7
Dividends and buybacks
Buyback yield–3.7%
Shareholder yield–3.7%
Ownership
Held by institutions8.9%12.9%
Held by insiders0.00%7.0%
Short interest, % of float–1.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.